论文部分内容阅读
目的对替比夫定治疗e抗原阳性慢性乙型肝炎的疗效进行探讨。方法 80例e抗原阳性慢性乙型肝炎患者随机分为对照组和实验组,每组40例,对照组实施拉米夫定治疗,实验组实施替比夫定治疗。结果治疗12周,两组的ALT复常率、HBV-DNA转阴率以及HBeAg血清学转换率相仿,差异无统计学意义(P>0.05);治疗24周,两组的ALT复常率、HBV-DNA转阴率相仿,差异无统计学意义(P>0.05),实验组的HBeAg血清学转换率比对照组高,差异有统计学意义(P<0.05);治疗48周,实验组的ALT复常率、HBV-DNA转阴率以及HBeAg血清学转换率明显比对照组高,差异有统计学意义(P<0.05)。结论采用替比夫定对e抗原阳性慢性乙型肝炎进行治疗,疗效确切,安全可靠,值得普及和应用。
Objective To investigate the efficacy of telbivudine in the treatment of e antigen-positive chronic hepatitis B. Methods Eighty patients with e antigen positive chronic hepatitis B were randomly divided into control group and experimental group, 40 cases in each group. The control group was treated with lamivudine, and the experimental group was treated with telbivudine. Results After 12 weeks treatment, ALT normalization rate, HBV-DNA negative rate and HBeAg seroconversion rate were similar between the two groups (P> 0.05). After treatment for 24 weeks, the ALT normalization rate, HBV-DNA negative rate was similar, the difference was not statistically significant (P> 0.05), the experimental group HBeAg seroconversion rate than the control group, the difference was statistically significant (P <0.05); 48 weeks, the experimental group ALT normalization rate, HBV-DNA negative rate and HBeAg seroconversion rate were significantly higher than the control group, the difference was statistically significant (P <0.05). Conclusion The treatment of e antigen positive chronic hepatitis B with telbivudine is effective and safe, which is worth popularizing and applying.